Alazard-Dany Nathalie, Ottmann Terrangle Michèle, Volchkov Viktor
Laboratoire des Filovirus, Inserm U758, ENS Lyon, IFR 128 BioSciences Lyon-Gerland, Université Claude Bernard Lyon 1, France.
Med Sci (Paris). 2006 Apr;22(4):405-10. doi: 10.1051/medsci/2006224405.
Ebola and Marburg viruses are the causative agents of rapidly progressive hemorrhagic fevers with high mortality rates. Pre- or post-exposure treatments against the diseases are currently not available for human use. In the field, establishment of strict quarantine measures preventing further virus transmission are still the only way to fight the infections. However, our knowledge of Ebola and Marburg viruses has markedly increased as a result of two recent discoveries discussed in this review. Chandran et al. have elucidated the mechanism by which Ebola GP is converted to a fusion-active form. Infectivity of Ebola virus was shown to be dependent on the cleavage of GP by cellular endosomal proteases, cathepsin B and L, thus opening new therapeutic approaches options. As for Jones SM et al., they have successfully vaccinated monkeys with recombinant vesicular stomatitis virus expressing Ebola or Marburg virus surface glycoprotein GP, a promising vaccine approach.
埃博拉病毒和马尔堡病毒是导致快速进展性出血热且死亡率很高的病原体。目前尚无针对这些疾病的暴露前或暴露后治疗方法供人类使用。在实际防控中,建立严格的检疫措施以防止病毒进一步传播仍然是对抗感染的唯一方法。然而,由于本综述中讨论的两项最新发现,我们对埃博拉病毒和马尔堡病毒的了解有了显著增加。钱德兰等人阐明了埃博拉病毒糖蛋白(GP)转化为融合活性形式的机制。研究表明埃博拉病毒的感染性取决于细胞内体蛋白酶组织蛋白酶B和L对GP的切割,从而开辟了新的治疗方法选择。至于琼斯·S·M等人,他们已成功用表达埃博拉病毒或马尔堡病毒表面糖蛋白GP的重组水疱性口炎病毒为猴子接种疫苗,这是一种很有前景的疫苗方法。